Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

July 30, 2020

– Strong global pipeline progress – three U.S. FDA¹Fast Track Designations; surufatinib U.S. NDA²preparations underway; and initiation of global Phase III for fruquintinib –

Bay Street News

» View More News for July 30, 2020